Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26879331 | 0.91 | BCHE (0.37) | SLC6A2BCHEMAPTCYP2C19PDPK1 | |
| SCHEMBL26879446 | 0.83 | TACR1 (0.36) | SLC6A2BCHETACR1MAPTACHE | |
| SCHEMBL26879300 | 0.83 | PSEN1 (0.39) | SLC6A2BCHEMAPTCYP2C19PDPK1 | |
| SCHEMBL26879276 | 0.83 | KMT2A (0.36) | SLC6A2TACR1TMEM97CARM1PRMT6 | |
| SCHEMBL26879302 | 0.83 | MAPT (0.35) | SLC6A2BCHEMAPTCYP2C19PDPK1 | |
| SCHEMBL26879312 | 0.82 | GRM5 (0.35) | SLC6A2BCHEMAPTCYP2C19PDPK1 | |
| SCHEMBL26878944 | 0.81 | SLC6A2 (0.39) | SLC6A2BCHEMAPTCYP2C19PDPK1 | |
| SCHEMBL26879065 | 0.81 | SLC6A2 (0.39) | SLC6A2BCHEMAPTCYP2C19PDPK1 | |
| SCHEMBL26879278 | 0.81 | SLC6A2 (0.44) | SLC6A2BCHEMAPTCYP2C19PDPK1 | |
| SCHEMBL26879066 | 0.81 | SLC6A2 (0.39) | SLC6A2BCHEMAPTCYP2C19PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | SLC6A2 3181/4885BCHE 2461/4885TACR1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.